AMAR Amarillo Biosciences Inc. featured news, full reports, and detailed charts
Amarillo Biosciences Inc. (AMAR/AMAR.OB) Wrap Up:
Amarillo Biosciences, Inc., a biotechnology company, engages in the research and development of utilization of low-dose, orally administered interferon as a treatment for various conditions comprising chronic cough, influenza, and opportunistic infections in patients who are HIV positive. The company has strategic alliances with Hayashibara Biochemical Laboratories, Inc.; Nobel Ilac Sanayii Ve Ticaret A.S; and Bumimedic (Malaysia) Sdn. Bhd; and CytoPharm, Inc. Amarillo Biosciences was founded in 1984 and is based in Amarillo, Texas.Amarillo Biosciences Inc. (AMAR:OTC Bulletin Board Market)
Snapshot of Amarillo Biosciences Inc. (AMAR)
|
OPEN
$0.18
|
PREVIOUS CLOSE
$0.18
|
|
|
DAY HIGH
$0.19
|
DAY LOW
$0.17
|
|
|
52 WEEK HIGH
09/3/09 - $0.30
|
52 WEEK LOW
03/25/09 - $0.04
|
|
|
MARKET CAP
8.6M
|
AVERAGE VOLUME 3 mo
87.7K
|
|
|
DILUTED EPS TTM
$-0.12
|
SHARES OUTSTANDING
47.9M
|
|
|
AMAR Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
AMAR Top Compensated Officers
Executives, Board Directors
Key developments for Amarillo Biosciences Inc. (AMAR)
Amarillo Biosciences Inc. has appointed Bernard Cohen as chief financial officer. Cohen succeeds Gary Coy, who will continue to assist the company with SEC filings as a consultant. He was most recently director of finance and database manager at Harrington Regional Medical Center in Amarillo, US.
Amarillo Biosciences Inc. announced that it has agreed to a strategic partnership with Intas Pharmaceuticals Ltd., whereby Intas will sponsor clinical trials of ABI's orally administered interferon-alpha lozenges in order to combat influenza. Intas will pay ABI a royalty on net sales after marketing approval is obtained in India. The objective of the clinical trials in India is to determine the efficacy of low dose oral interferon in reducing the severity of infection with influenza viruses such as H1N1. ABI has been conducting studies on the use of low-dose interferon to treat and prevent respiratory tract disease in animals and has found it to be a safe, effective oral therapy for cats, cattle, and horses. In a Phase 2 clinical trial being conducted in Perth, Western Australia, volunteers are being given ABI's low-dose oral interferon for prevention and treatment of influenza. The study, which is being conducted by researchers at the University of Western Australia and funded by the Health Department of Western Australia, is nearing completion. This double-blind, placebo-controlled trial is expected to show that ABI's orally administered interferon lozenges can safely reduce both the infection rate and the severity of symptoms in subjects who are exposed to influenza and other respiratory viruses during a typical flu season. The company plans to release the results of this important study before the end of 2009.
Amarillo Biosciences Inc. announced that it has hired Bernard Cohen to be a Vice-President and Chief Financial Officer (CFO) of the company. Cohen replaced Dr. Gary Coy, Ph.D., who resigned September 4, 2009. Cohen will be involved in all financial and accounting affairs of the company. Cohen's position with the company began October 1, 2009 and is to continue indefinitely. His position with the company is terminable by him or the company upon three (3) months written notice. His employment is governed by a written contract entered into by him and the company on October 1, 2009, which has been approved by the Board of Directors of the company.
AMAR Competitors
| Company | Last | Change | |
| No competitor information is available for AMAR. | |||
| Market data is delayed at least 20 minutes. | |||
Industry Analysis
| Valuation | AMAR | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 98.2x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 83.0x |
|
|
AMAR |
||
AMAR transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Amarillo Biosciences Inc.
More news for AMAR
AMARILLO BIOSCIENCES INC Files SEC form 10-Q, Quarterly Report
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion should be read in conjunction with our financial statements and the notes thereto which appear elsewhere in this report. The results shown herein are not necessarily indicative of the results to be expected in any future periods. This discussion contains forward-looking statements based on current expectations, which involve uncertainties. Actual results and the timing of events could differ materially from the forward-looking statements as a result of a number of factors. Readers should also carefully review factors set forth in other reports or documents that we file from time to time with the Securities and Exchange Commission. Company Goal - FDA Approval and Commercialization of Oral Interferon. Amarillo Biosciences, Inc. (OTCBB: AMAR), is the world leader in the development of low-dose interferon for oral delivery and is conducting Phase 2 clinical studies testing oral interferon in animal and human diseases. We have changed our focus from Orphan Diseases (small markets) to treatment of diseases with large markets to attract large pharma partners. Our funding strategy is to seek private placement and partner funding to complete Phase 2 clinical studies for influenza, chronic cough in COPD patients, and hepatitis C; then seek large pharma partners to fund and help with the regulatory approval process in the US and Europe. We believe that our technology and the large billion dollar markets for these disease indications will attract global pharma partners sometime next year. Intellectual Property Our portfolio consists of patents with claims that encompass method of use or treatment with interferon and composition of matter and manufacturing. We currently own or license nine patents and four pending patents related to low-dose orally delivered interferon, and one issued patent on our dietary supplement. We have completed more than 100 pre-clinical (an...Click here to read the whole Article (external link)
Amarillo Biosciences Comments on New Findings of H1N1 in Animals and Potential Effect on Human Infections
AMARILLO, TX--(Marketwire - 11/11/09) - Amarillo Biosciences, Inc. (ABI) (OTC.BB:AMAR - News) reported that the American Veterinary Medical Association (AVMA) recently confirmed that a household cat in Iowa developed signs of respiratory infection caused by H1N1 influenza virus. The AVMA report adds cats to the growing list of animals, including ferrets, hogs (most recently in Indiana and Taiwan) and turkeys reported to be infected by H1N1 influenza virus. The present pandemic H1N1 is a swine virus, meaning it has already acquired genetic information from viruses that co-infect swine. The report of jumps of the H1N1 virus from humans into hogs, ferrets, cats and turkeys increases worries that the H1N1 virus can readily jump to many species. Transmission of H1N1 virus to hogs has been reported at an increasing frequency. Flu infections in hogs in Europe, Asia, Australia and North America have now been reported.The Centers for Disease Control and Prevention (CDC) (http://www.cdc.gov) maintains an H1N1 Flu Situation Update at http://www.cdc.gov/h1n1flu/update.htm, which reports a widespread pandemic occurring in 48 states. T...Click here to read the whole Article (external link)
Berkshire Sells $21.6M Worth of Moodys
Moodys Corp (MCO) Berkshire Hathaway Inc BO 794,388 $21,626,719 J Crew Group (JCG) Drexler Millard S CEO,DIR, BO 500,000 $16,220,907 Fossil (FOSL) Kartsotis Tom CB,DIR, BO 358,562 $9,244,400 Gartner (IT) Silver Lake Partners LP BO 216,033 $3,587,145 Microsoft (MSFT) Turner Brian Kevin COO 87,728 $2,103,204 Interline Brandsde (IBI) Jacquet Ernest K DIR 103,185 $1,656,219 Medassets (MDAS) Bardis John A CB,CEO, PR,DIR 70,000 $1,552,838 Prudential Financial (PRU) Grier Mark B VCB,DIR 32,000 $1,538,560 Markel (MKL) Markel Steven A VCB,DIR 3,700 $1,197,721 Rovi (ROVI) Amoroso Alfred J CEO,PR, DIR 39,500 ...Click here to read the whole Article (external link)
AMARILLO BIOSCIENCES INC Financials
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...Click here to read the whole Article (external link)
Dr. Manfred Beilharz, Co-Investigator in Australian Influenza Phase 2 Clinical Trial, Interviewed on 6PR Nightline Program Regarding Interferon and Influenza
AMARILLO, TX--(Marketwire - 08/17/09) - Amarillo Biosciences, Inc. (ABI) (OTC.BB:AMAR - News) today announced that Dr. Manfred Beilharz, Chairman of the Department of Microbiology and Immunology, School of Biomedical, Biomolecular and Chemical Sciences at the University of Western Australia, was recently interviewed by Graham Mabury on 6PR Nightline, a radio program in Australia. Dr. Beilharz is a co-investigator of the ongoing Phase 2, 200-subject clinical trial that is testing the efficacy of ABI's oral interferon alpha in preventing influenza and winter colds. Dr. Beilharz discusses the development history and mechanism of action of oral interferon as well as the ongoing Phase 2 clinical trial in Perth, Australia in which 200 healthy volunteers are taking oral interferon lozenges provided by Amarillo Biosciences, Inc. or a matching placebo once a day for 16 weeks as a prevention for winter colds and influenza. The interview can be heard at: http://www.amarbio.com/index.php?option=com_content&view=article&id=85&Itemid=100013About Amarillo BiosciencesAmarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 7% of Amarillo Biosciences shares and has provided over $18 million in ...Click here to read the whole Article (external link)